PDCD1 and myocarditis: The risk of myocarditis may differ between various classes of immune checkpoint inhibitors with anti-CTLA-4 monotherapy (3.3%), anti-PD-L1 (2.4%), and anti-PD-1 agents (0.5%) [83].